Bluebird preps for first commercial use of sickle cell gene therapy
Bio Pharma Dive
MAY 6, 2024
A 12-year-old boy in the Washington, D.C., area is set become the first patient treated with Lyfgenia since its U.S. approval last December.
Mon.May 06, 2024
312 
IPC and CSIR-IMTech forge strategic partnership to advance research in microbiology
AuroBlog - Aurous Healthcare Clinical Trials blog
MAY 6, 2024
Aimed at driving innovation and progress in the field of microbiology, the Indian Pharmacopoeia Commission (IPC) and the CSIR-Institute of Microbial Technology (IMTech), Chandigarh, have joined forces towards advancing microbiological research and development for the betterment of public health.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
As drug shortages reach record highs, regulators weigh next steps
Bio Pharma Dive
MAY 6, 2024
With many chemotherapy and ADHD drugs stuck in stubbornly short supply, several agencies are looking for new solutions.
UK MHRA approves ViiV Healthcare’s cabotegravir formulations for HIV-1
Pharmaceutical Technology
MAY 6, 2024
The UK MHRA approved two formulations of ViiV Healthcare’s cabotegravir, offering a new prevention option for HIV-1 infection.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
AstraZeneca ups stake in Cellectis in latest cell therapy bet
Bio Pharma Dive
MAY 6, 2024
The British drugmaker, which has made genetic medicine a larger priority of late, added $140 million to a deal to develop up to 10 gene and cell therapies.
Scientists Reveal Optimal Daily Ratio of Sitting, Standing, Sleeping And Movement
AuroBlog - Aurous Healthcare Clinical Trials blog
MAY 6, 2024
People have a pretty intuitive sense of what is healthy – standing is better than sitting, exercise is great for overall health and getting good sleep is imperative.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Lantern Pharma and Oregon partner to develop cancer treatment
Pharmaceutical Technology
MAY 6, 2024
Lantern Pharma has entered into a partnership with Oregon for optimising the development of XCE853, through an AI-driven approach.
Free pathway analysis: How much do you really save?
Bio Pharma Dive
MAY 6, 2024
Can free bioinformatics tools get the job done?
BioNTech plots first wave of cancer launches in 2026 as COVID vaccine sales continue to disappoint
Fierce Pharma
MAY 6, 2024
As BioNTech continues to endure a sharp decline in COVID-19 vaccine sales, the German mRNA specialist is looking ahead to the next leg of its commercial journey. | With plans to have at least 10 potentially registrational trials underway by the end of 2024, BioNTech is plotting the first wave of its market debut in oncology from 2026 onward.
Maximizing efficiency in translational medicine with an on-site pharmacy
Bio Pharma Dive
MAY 6, 2024
The ability to modify drug formulations in real time and dosage strengths is crucial, while adhering to all regulatory standards and maintaining cGMP standards.
Cipla and Glenmark initiate recall of certain products in the US
Pharmaceutical Technology
MAY 6, 2024
Cipla and Glenmark Pharmaceuticals are recalling specific products from the US market due to distinct manufacturing issues.
Optimized trials are the easiest way to meet the FDA’s latest diversity requirements
Bio Pharma Dive
MAY 6, 2024
Optimized clinical trials will help sponsors align with new FDORA diversity requirements.
Sentynl acquires Eiger’s Zokinvy for progeria treatment
Pharmaceutical Technology
MAY 6, 2024
Sentynl Therapeutics has announced the acquisition of Zokinvy programme from Eiger BioPharmaceuticals for the treatment of progeria.
Amneal agrees to $272.5M settlement to resolve opioid lawsuits
Fierce Pharma
MAY 6, 2024
Amneal Pharmaceuticals has agreed to pay $272.5 million to settle approximately 900 lawsuits brought by state, local and Native American jurisdictions claiming that the New Jersey generics producer | Amneal Pharmaceuticals has agreed to pay $272.5 million to settle approximately 900 lawsuits brought by state, local and Native American jurisdictions claiming that the New Jersey generics producer fueled the opioid crisis by failing to act on suspicious opioid orders.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Top charities team up with $300m for climate, health equity
pharmaphorum
MAY 6, 2024
The Novo Nordisk Foundation, the Bill & Melinda Gates Foundation, and Wellcome have joined forces to tackle some of the most pressing threats to human health and wellbeing. The new initiative gets underway with $300 million in funding over three years earmarked for handling infectious diseases and antimicrobial resistance (AMR), addressing climate change, and raising our understanding of how nutrition can impact immunity, disease, and the development of children.
Pfizer hires Citi analyst Andrew Baum to manage portfolio strategy, business development
Fierce Pharma
MAY 6, 2024
“Our next question will come from Andrew Baum with Citi.” | Citi analyst Andrew Baum, after covering Pfizer for more than a decade, will join the Big Pharma company as chief strategy and innovation officer. In the role, he'll oversee the drugmaker's portfolio management and business development activities.
The Promise of RFID for Improving Medication Inventory Management
Pharmaceutical Commerce
MAY 6, 2024
Radio frequency identification (RFID) not only helps hospitals boost their medication safety standards, as it also allows clinicians to continue to provide quality patient care.
ADC Therapeutics touts early Zynlonta results in marginal zone lymphoma, raises $105M through share sale
Fierce Pharma
MAY 6, 2024
In a flurry of updates Monday, ADC Therapeutics revealed that it's selling $105 million in new shares while also touting results for antibody-drug conjugate Zynlonta from a small investigator-initi | ADC Therapeutics provided several company updates Monday, including that it's raising $105 million through a sale of common shares and pre-funded warrants.
Boehringer raises hope of diabetic macular ischaemia therapy
pharmaphorum
MAY 6, 2024
Boehringer drug shows promise in diabetic macular ischaemia (DMI), a common and irreversible complication of the eye in people with diabetes with no approved therapies
Can a Device Be Found Not Substantially Equivalent Because of Cybersecurity Risks? A Review of FDA’s Draft Guidance on Cybersecurity in Medical Devices
FDA Law Blog
MAY 6, 2024
By Lisa M. Baumhardt, Senior Medical Device Regulation Expert & Adrienne R. Lenz, Principal Medical Device Regulation Expert — FDA recently issued a draft guidance which would update the agency’s Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions guidance. The draft guidance provides recommendations on what is required to meet cybersecurity obligations under section 524B of the Food, Drug and Cosmetic Act (FD&C).
Activist investor urges changes to Novavax board
pharmaphorum
MAY 6, 2024
Shah Capital has stepped up its campaign for change at vaccine producer Novavax, lobbying against the re-election of three directors and executive pay packages in a letter to fellow stockholders. The hedge fund says it wants to send a “strong and clear message” to the board at Novavax, reiterating the claim – first made a few weeks ago – that the company is “being hindered by an overly conservative board and management that clings to failed strategies.
Changing Perspectives on Clinical Research Through Mindfulness and Professionalism
ACRP blog
MAY 6, 2024
On Day Two of ACRP 2024 in Anaheim, Calif., attendees were invited to take advantage of “the power of pause” to calm down their overstressed and nonstop brains, while on Day Three, they were encouraged to think of each day as Day One for making the kinds of incremental changes that will lead to clinical research being recognized widely as profession and clinical trials as a clinical care option.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharma Pulse 5/6/24: Are Smartphones Driving Teens to Depression? Does Pharma Know What Their Customers Really Want? & more
Pharmaceutical Commerce
MAY 6, 2024
The latest news for pharma industry insiders.
Citi analyst Andrew Baum to head Pfizer strategy team
pharmaphorum
MAY 6, 2024
Pfizer has named Citi analyst Andrew Baum as its chief strategy and innovation officer, taking point on portfolio management and capital deployment
ASGCT 2024 Comes at Pivotal Time for Gene and Cell Therapy Sector
BioSpace
MAY 6, 2024
Jeffrey Chamberlain, president of the American Society of Gene & Cell Therapy, spoke with BioSpace about what we can expect to learn about in Baltimore this week.
How Pharma Can Harness Education to Transform the Health Journey
Fierce Pharma
MAY 6, 2024
As patients increasingly drive their own healthcare journeys, many rely on educational resources to figure out what actions to take. | Discover how effective education empowers patients and drives healthier outcomes in healthcare.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
ASGCT24: On the Ground in Baltimore
BioSpace
MAY 6, 2024
BioSpace will be in attendance at the American Society of Gene & Cell Therapy’s 27th annual meeting, along with thousands of others. Stay with us for updates throughout the week.
Which pharmaceutical companies have the most SPCs in France?
Drug Patent Watch
MAY 6, 2024
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in France.
The Next Frontier: Industrializing Cell Therapy Manufacturing
BioSpace
MAY 6, 2024
Q&A: Development Scientist at AGC Biologics Sara Morlacchi analyzes the growth of the cell therapy industry and barriers for cost and accessibility.
New patent for Vertex Pharms drug SYMDEKO (COPACKAGED)
Drug Patent Watch
MAY 6, 2024
Annual Drug Patent Expirations for SYMDEKO+%28COPACKAGED%29 Symdeko (copackaged) is a drug marketed by Vertex Pharms Inc and is included in one NDA. It is available from one supplier.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content